Results 101 to 110 of about 42,124 (246)

Microbial metabolite indole‐3‐propionic acid preserves astrocytic mitochondrial mitofusin 2 to limit neuroinflammation after traumatic brain injury

Interdisciplinary Medicine, EarlyView.
Following traumatic brain injury, indole‐3‐propionic acid (IPA) directly targets the aryl hydrocarbon receptor on astrocytes in the peri‐lesional cortex; this suppresses interferon regulatory factor 1‐driven transcription of the E3 ubiquitin ligase RFFL (ring finger and FYVE‐like domain containing E3 ubiquitin protein ligase).
Ziwen Zhang, Kai Wang, Liangbo Wang, Wencong Li, Hao Guo, Meng Xu, Tinghao Wang, Jiahui Ren, Ting Zhu, Jiahui Wang, Wenxing Cui, Jinpeng Zhou, Yang Tian, Liying Han, Chengxuan Guo, Shuoyao Ma, Qiang Wang, Zhihong Li, Yaning Cai, Jingyu Dong, Xun Wu, Haixiao Liu, Yan Qu   +22 more
wiley   +1 more source

Identification of a Putative Protein Profile Associated with Tamoxifen Therapy Resistance in Breast Cancer

, 2009
Tamoxifen resistance is a major cause of death in patients with recurrent breast cancer. Current clinical factors can correctly predict therapy response in only half of the treated patients.
Kang, H, Timmermans, Mieke, Martens, John, Look, Maxime, den Bakker, Michael, Luider, Theo, Gelder, Marion, Foekens, John, Pasa-Tolic, L, Umar, Arzu, Jaitly, N   +10 more
core  

Risk Factors Influencing Efficacy and Prognosis Evaluation of Neoadjuvant Systemic Therapy in Triple‐Positive Breast Cancer

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT To identify the determinants of the response to neoadjuvant systemic therapy (NST) in triple‐positive breast cancer (TPBC), we retrospectively enrolled 520 patients with human epidermal growth factor receptor 2 (HER2)‐positive breast cancer who were treated at The First Affiliated Hospital of Chongqing Medical University between January 2015 ...
Lin‐Rui Miao, Hao Liu, Hai‐Ying Yu, Jian Chen, Ming‐Yu Yang, Ya‐Lan Zhang, Gang Tu, Ling‐Feng Tang   +7 more
wiley   +1 more source

TARBP2-Enhanced Resistance during Tamoxifen Treatment in Breast Cancer

, 2019
Tamoxifen is the most widely used hormone therapy in estrogen receptor-positive (ER+) breast cancer, which accounts for approximately 70% of all breast cancers.
Yu-Jhen Lyu, Yao-Lung Kuo, Pai-Sheng Chen, Jie-Ning Li, Hsin-Yi Huang, Hung-Yu Sun, Ming-Yang Wang, Bo-Rong Chen, Chiao Lo   +8 more
core   +1 more source

Data‐Independent Acquisition Mass Spectrometry in Tumor Classification and Cancer Biomarker Research

Mass Spectrometry Reviews, EarlyView.
Abstract Cancer treatment is far from optimal also because current classification systems do not reflect the complex molecular status of the tumor and its phenotype in sufficient detail. To construct molecular tumor classifiers, omics tools provide complex molecular data reflecting many aspects from genotype to phenotype.
Jan Simonik, Petr Lapcik, Pavla Bouchalova, Pavel Bouchal   +3 more
wiley   +1 more source

Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity

Cell Reports, 2015
Breast cancers (BCs) typically express estrogen receptors (ERs) but frequently exhibit de novo or acquired resistance to hormonal therapies. Here, we show that short-term treatment with the anti-estrogens tamoxifen or fulvestrant decrease cell ...
Bruno M. Simões, Ciara S. O’Brien, Rachel Eyre, Andreia Silva, Ling Yu, Aida Sarmiento-Castro, Denis G. Alférez, Kath Spence, Angélica Santiago-Gómez, Francesca Chemi, Ahmet Acar, Ashu Gandhi, Anthony Howell, Keith Brennan, Lisa Rydén, Stefania Catalano, Sebastiano Andó, Julia Gee, Ahmet Ucar, Andrew H. Sims, Elisabetta Marangoni, Gillian Farnie, Göran Landberg, Sacha J. Howell, Robert B. Clarke   +24 more
doaj   +1 more source

Current Cell/Organoid and Animal Models for Primary Sclerosing Cholangitis

Portal Hypertension &Cirrhosis, EarlyView.
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease with limited therapeutic options and a marked risk of progression to biliary fibrosis, cirrhosis, and malignancy. Progress in PSC research has been hindered by the lack of models that faithfully recapitulate the complex biliary microenvironment and disease heterogeneity ...
Qigu Yao, Sheng Cheng, Qiaoling Pan, Jiong Yu, Hongcui Cao   +4 more
wiley   +1 more source

Targeting lipid metabolism to overcome tamoxifen resistance in breast cancer: Evaluating the synergistic therapeutic potential of quercetin

Cancer Treatment and Research Communications
Breast cancer remains the most prevalent malignancy among women globally, with hormone receptor-positive subtypes representing the majority of cases. Despite significant advances in treatment, resistance to Tamoxifen, a cornerstone therapy for estrogen ...
Radwa M. Rifaat, Marwa W. Kamel, Marwa Sharaky, Yasmin M. Attia, Samia A. Shouman   +4 more
doaj   +1 more source

Intelligent nano‐platforms in breast cancer therapy: Current advances and future perspectives

Precision Medical Sciences, EarlyView.
The smart nano platform in breast cancer treatment is designed with advanced nanocarriers, including liposomes, hydrogels, porous nanoparticles, and aptamer‐based systems. These systems are capable of targeted drug release and response to environmental stimuli.
Tina Rahimi, Moluk Aivazi
wiley   +1 more source

Endocrine therapy‐induced cancer‐related fatigue in hormone‐dependent malignancies: Mechanisms, impact, and management strategies

Precision Medical Sciences, EarlyView.
Multipathway schematic of endocrine therapy–induced cancer‐related fatigue. Endocrine interventions trigger four interacting mechanisms—neuroendocrine dysregulation, systemic inflammation, energy‐metabolic failure, and psycho‐behavioral amplification—that culminate in the multidimensional CRF phenotype.
Jiajing Jiang, Jun Lu, Sen Qin, Ruzhou Chen, Qiuchen Zhang, Lvqi He, Yubei Li, Jingyao Yan   +7 more
wiley   +1 more source